Predict your next investment

Diversified Financial Services
bpifrance.fr

See what CB Insights has to offer

Investments

1234

Portfolio Exits

115

Funds

9

Partners & Customers

10

About Bpifrance

Bpifrance (Banque Publique d'Investissement) assists companies by booting up their listing on the stock exchange and offering credit to equity. BPI France provides companies a continuum of funding at every stage of their development.

Bpifrance Headquarter Location

27-31 Avenue du General Leclerc

Maisons-Alfort, 94710,

France

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Bpifrance

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Bpifrance in 1 Expert Collection, including Sovereign Wealth Funds.

S

Sovereign Wealth Funds

22 items

The world's most active sovereign wealth funds investing in private tech companies.

Research containing Bpifrance

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Bpifrance in 3 CB Insights research briefs, most recently on Aug 5, 2021.

Latest Bpifrance News

Valneva Announces Successful Outcome of its AGM and Appointment of two New Supervisory Board Members

Jun 24, 2022

Nantes, FRANCE Saint-Herblain (France), June 24, 2022 – Valneva S E (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting (AGM) held yesterday in Paris. Among the adopted resolutions were approval of the 2021 financial statements, delegations for the management board to increase Valneva’s share capital and/or issue financial instruments, and the appointment, for a three-year term, of two new Supervisory Board members. Bpifrance Participations was appointed to Valneva’s Supervisor Board and will be represented by Maïlys Ferrère. Ms. Ferrère, a French national, is Director of Large Venture Investments at Bpifrance, France’s state-owned investment bank. In her role at Bpifrance, she sits on various boards of Euronext-listed companies. Before joining Bpifrance Large Venture in 2013, Ms. Ferrère was an Investment Director at the Fonds Stratégique d’Investissement. Prior to this, Ms. Ferrère had a career in the banking industry, focusing on equity capital markets in various financial institutions. She graduated from Institut d’Etudes Politiques de Paris. James Edward Connolly, an American national, was also appointed to Valneva’s Supervisory Board. Mr. Connolly is a seasoned business executive with more than three decades of experience in the life sciences industry. Since 2013, Mr. Connolly has been serving on a number of boards for a variety of vaccine, biopharmaceutical and investment organizations. From 2010 to 2013, Mr. Connolly was President and CEO of Aeras (now IAVI.) Prior to this, he had a long and successful 24-year career at Wyeth (now Pfizer), where he held a series of senior roles, the last two of which were Executive Vice President and General Manager, Wyeth Vaccines and President, Wyeth Canada. During his tenure leading Wyeth Vaccines, Mr. Connolly played a leading role building the company’s vaccines business into one of the top four global manufacturers and creating the first true blockbuster vaccine, Prevnar, with sales in excess of $3 billion. Additionally, the term of office of Supervisory Board members Frédéric Grimaud, James Sulat, and Anne-Marie Graffin was renewed until June 2025. In a separate meeting, Frédéric Grimaud was re-elected as Chairman of Valneva’s Supervisory Board. Valneva also confirmed during the AGM that initiation of the Phase 3 study of Lyme disease vaccine candidate VLA15 is planned in the third quarter of 2022 and that it is expecting to submit the Biologics License Application (BLA) for its chikungunya vaccine candidate VLA1553 to the Food and Drug Administration (FDA) in the second half of 2022. The AGM’s voting results will be made available in the “ Investors & Media ” section of Valneva’s corporate website in the coming days. About Valneva SE Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19. Media & Investor Contacts

Bpifrance Investments

1,234 Investments

Bpifrance has made 1,234 investments. Their latest investment was in Arterya as part of their Seed on June 6, 2022.

CBI Logo

Bpifrance Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/24/2022

Seed

Arterya

$1.06M

Yes

1

6/24/2022

Seed

Conformitee

$1.58M

Yes

1

6/23/2022

Grant - III

Osivax

$10.52M

No

1

6/23/2022

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

6/21/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/24/2022

6/24/2022

6/23/2022

6/23/2022

6/21/2022

Round

Seed

Seed

Grant - III

Seed VC

Series A

Company

Arterya

Conformitee

Osivax

Subscribe to see more

Subscribe to see more

Amount

$1.06M

$1.58M

$10.52M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

10

Bpifrance Portfolio Exits

115 Portfolio Exits

Bpifrance has 115 portfolio exits. Their latest portfolio exit was Rapidle on June 23, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/23/2022

Acquired

$99M

1

6/7/2022

Acquired

$99M

1

6/2/2022

Asset Sale

$99M

2

6/1/2022

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

5/24/2022

Corporate Majority

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/23/2022

6/7/2022

6/2/2022

6/1/2022

5/24/2022

Exit

Acquired

Acquired

Asset Sale

Acquired

Corporate Majority

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

1

2

10

10

Bpifrance Acquisitions

46 Acquisitions

Bpifrance acquired 46 companies. Their latest acquisition was LV Overseas on January 31, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/31/2022

$99M

Acq - Fin - II

1

7/22/2021

$99M

Acq - Fin

3

12/17/2020

$99M

Acq - Fin

1

11/27/2020

Subscribe to see more

$99M

Subscribe to see more

10

3/12/2020

Other Venture Capital

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/31/2022

7/22/2021

12/17/2020

11/27/2020

3/12/2020

Investment Stage

Other Venture Capital

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

Note

Acq - Fin - II

Acq - Fin

Acq - Fin

Subscribe to see more

Subscribe to see more

Sources

1

3

1

10

10

Bpifrance Fund History

9 Fund Histories

Bpifrance has 9 funds, including Bpifrance Hexagone 1 FPCI.

Closing Date

Fund

Fund Type

Status

Amount

Sources

9/4/2020

Bpifrance Hexagone 1 FPCI

$49.24M

1

5/25/2020

LAC 1

$99M

10

12/4/2017

Digital Health Fund

$99M

10

11/20/2017

Defense Investment Vehicle

$99M

10

9/14/2016

BPI France SME Fund

$99M

10

Closing Date

9/4/2020

5/25/2020

12/4/2017

11/20/2017

9/14/2016

Fund

Bpifrance Hexagone 1 FPCI

LAC 1

Digital Health Fund

Defense Investment Vehicle

BPI France SME Fund

Fund Type

Status

Amount

$49.24M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

Bpifrance Partners & Customers

10 Partners and customers

Bpifrance has 10 strategic partners and customers. Bpifrance recently partnered with Mubadala on December 12, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

12/5/2021

Partner

United Arab Emirates

Mubadala inks $6.11bn deals to invest in French priority sectors

Nicolas Dufourcq , CEO of Bpifrance , stated : `` We are proud of this major step forward in our partnership with Mubadala Investment Company , which was initiated in 2014 .

1

12/4/2021

Partner

United Arab Emirates

Mubadala signs two agreements to facilitate investments in priority sectors in France

Existing co-investment partnerships between Mubadala Investment Company and Bpifrance is extended with an additional € 4 billion joint commitment .

2

6/30/2021

Partner

United Arab Emirates

BpiFrance and Mubadala form African Private Equity Platform

Bpifrance and Mubadala Investment Company have worked together since the launch of the French Emirati Fund in 2014 and the Innovation Partnership in 2017 , with approximately EUR 1 billion of joint investments in French companies , and a EUR 1 billion commitment by Mubadala Investment Company into Bpifrance 's flagship Lac1 Fund dedicated to listed French multinationals .

1

2/2/2021

Partner

Japan

Subscribe to see more

Subscribe to see more

10

11/4/2020

Partner

France

Subscribe to see more

Subscribe to see more

10

Date

12/5/2021

12/4/2021

6/30/2021

2/2/2021

11/4/2020

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

United Arab Emirates

United Arab Emirates

United Arab Emirates

Japan

France

News Snippet

Mubadala inks $6.11bn deals to invest in French priority sectors

Nicolas Dufourcq , CEO of Bpifrance , stated : `` We are proud of this major step forward in our partnership with Mubadala Investment Company , which was initiated in 2014 .

Mubadala signs two agreements to facilitate investments in priority sectors in France

Existing co-investment partnerships between Mubadala Investment Company and Bpifrance is extended with an additional € 4 billion joint commitment .

BpiFrance and Mubadala form African Private Equity Platform

Bpifrance and Mubadala Investment Company have worked together since the launch of the French Emirati Fund in 2014 and the Innovation Partnership in 2017 , with approximately EUR 1 billion of joint investments in French companies , and a EUR 1 billion commitment by Mubadala Investment Company into Bpifrance 's flagship Lac1 Fund dedicated to listed French multinationals .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

1

10

10

Bpifrance Team

8 Team Members

Bpifrance has 8 team members, including current Managing Director, Luc Heinrich.

Name

Work History

Title

Status

Luc Heinrich

Managing Director

Current

Menele Chesnot

Senior Director

Current

Romain Fourcade

Aviva, and iXO Private Equity

Senior Director

Current

Chahra Louafi

CDC Entreprises

Senior Director

Current

Olivier Martinez

CDC Entreprises, and Bioam Gestion

Senior Director

Current

Name

Luc Heinrich

Menele Chesnot

Romain Fourcade

Chahra Louafi

Olivier Martinez

Work History

Aviva, and iXO Private Equity

CDC Entreprises

CDC Entreprises, and Bioam Gestion

Title

Managing Director

Senior Director

Senior Director

Senior Director

Senior Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.